NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for NovoCure Ltd. To summarize, we found that NovoCure Ltd ranked in the 95th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 4318.5%. The most interesting components of our discounted cash flow analysis for NovoCure Ltd ended up being:
In the past 1.5 years, NovoCure Ltd has a compound free cash flow growth rate of 3.93%; that's higher than 95.1% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.19% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
NovoCure Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
MNKKQ, CYH, AMEH, RDY, and BEAT can be thought of as valuation peers to NVCR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
NovoCure Ltd. is pulling back Monday and the weakness may not be over. In early November we reviewed the charts of NVCR and wrote that, "If you are still long NVCR from early October then I would continue to hold those positions but raise stop protection to a close below $110 now." In the updated daily Japanese candlestick chart of NVCR, below, we can see some upper shadows last month telling us that traders were rejecting the highs.
NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 207,910 shares of NovoCure stock in a transaction dated Friday, December 18th. The shares were sold at an average price of $157.39, for a total value of $32,722,954.90. Following the transaction, the chief executive officer now directly owns 301,587 shares in the company, valued at approximately $47,466,777.93. The […]